Clinical response to bypassing agents (BPA) may vary between patients. Surgery is a particular situation which requires effective hemostasis during the procedure and for several days postoperatively, in order to obtain satisfactory wound healing. However, the optimal dose of BPA in different surgical situations has not been clearly established. We report here a prospective assessment of thrombin generation test (TGT) in monitoring the effectiveness of BPA during 10 elective invasive procedures performed in 6 patients with severe hemophilia and high-titre inhibitors. A standardized 3 step-protocol was used in all cases to individually tailor BPA. Thrombin generating capacity of patients increased after in-vitro and ex-vivo addition of BPA in a dose-dependent manner.
INTRODUCTION
The development of inhibitors is one of the most serious complications of hemophilia and bleeding episodes are more difficult to control in these patients (1) .Several studies have reported excellent efficacy of FEIBA ® (Baxter,Vienna,Austria) and NovoSeven ® (NovoNordisk,Copenhagen,Denmark) in 80 to 85% of cases (2) (3) (4) .Nevertheless,the presence of an inhibitor demands extremely cautious surgical management of patients in a multidisciplinary environment with appropriate surgical technique and effective haemostatic control.Moreover,the clinical response to BPA may be variable between patients.The optimal use of BPA is hampered by a lack of laboratory assays to monitor efficacy and determine adequate dosing. Recently,we described the first application of TGT in a surgical setting showing that the assay might be useful in guiding the choice of the most effective therapeutic option in inhibitor patients (5) .We report now a prospective clinical assessment of TGT and our results show a correlation between thrombin generation(TG) capacity and the clinical outcome of patients.
MATERIALS and METHODS

Subjects & Surgical Procedures:
The correlation between the clinical and the biological efficacy of BPA measured by TGT was prospectively evaluated in ten surgical procedures.Six patients with severe hemophilia A and high titer inhibitors(>5 BU/mL), undergoing elective surgeries were treated and documented after obtaining informed consent in accordance with the Declaration of Helsinki. The study was approved by the Lyon University Hospital's ethical committee.
The control population comprised 96 healthy males (40.2 years±11;mean±SD),not using drugs known to affect the coagulation system and without history of bleeding or thrombosis.
Study Design: Dose tailoring of BPA was performed using a standardised three-step-protocol including i)in-vitro spiking experiments evaluating the TG ability of increasing concentrations of NovoSeven ® (0-90-180-200-240-270 µg/kg) and Feiba ® (0-75-100 U/kg) in order to determine the minimal dose of each BPA that normalizes TG capacity ;ii)ex-vivo confirmation step where TG is measured before and after the administration of the BPA which gave the best haemostatic profile in the previous in-vitro spiking experiment using the dose which fully normalized in-vitro TG and iii)monitoring of the chosen dose of the BPA during the surgery and postoperative period.
As NovoSeven ® induces FXa and FIXa generation on activated platelets (6, 7) , the haemostatic efficacy of NovoSeven ® was evaluated using platelet rich plasma (PRP) (8) .Feiba,having a different mechanism of action,was evaluated using platelet poor plasma (PPP) (9) .
Blood and PPP&PRP Samples:
Venous blood was collected into citrated Monovette ® tubes(Sarstedt,Orsay,France) loaded with corn trypsin inhibitor 1.45µM(Haematologic Technologies,USA).PPP and PRP were obtained as previously described (10) (11) (12) .
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Routine measurements: FVIII activity was measured using BioMerieux-deficient-FVIII kit(Marcy l'Etoile,France).Anti-FVIII antibody levels were determined by the Bethesda assay as previously described (13) .
TG measurement: TG was measured using the calibrated automated TGT (CAT, Thrombinoscope bv, Maastricht, The Netherlands) and a Fluoroscan Ascent fluorometer (Thermolabsystems OY, Helsinki, Finland) as previously described (10) (11) (12) ,using TF1pM and phospholipids 4µM(final concentrations).PRP samples were tested with TF1pM only. Results were available in three hours following blood drawing.The analysis of the main TGT parameters i.e.peak,ETP(endogenous thrombin potential) and TG-rate,showed a certain correlation between clinical bleeding phenotype and both ETP and TG-rate.However the large variability of TG-rate in normal control PRPs makes it difficult to reliably determine normal values for this parameter.The peak can not be chosen as the peak values obtained in PRP cannot be compared to those obtained in PPP. In this study,we therefore used ETP as the main biological parameter.
RESULTS and DISCUSSION
Normal ETP values determined in 96 controls were 1487±186nM.min(mean±SD) in PPP and 1544±178nM.min(mean±SD) in PRP.
Table1 summarizes patient's characteristics,surgeries,ETP obtained with the three-step-protocol,BPA regimen and clinical outcome for each patient.TG was systematically measured before and one hour after each infusion of BPA during the surgery and every morning before a new infusion,to evaluate the residual TG activity of the patient.Intraoperative blood loss was quantified by measuring irrigation fluid and weighing surgical sponges used for blood and fluid collection during surgery.
Case #1:
The patient was clinically a bad responder to Feiba ® and he reported a weaker efficacy of NovoSeven ® 90µg.kg -1 during his last bleeding episode.According to TGT results,the surgery was performed using NovoSeven ® 200µg.kg -1 .Another high dose of 200µg.kg -1 was infused 2h later,followed by the usual regimen of 90µg.kg -1 every 2h.On the 2 nd postoperative day NovoSeven ® 90µg.kg -1 was given every 3h before starting continuous infusion with a dosage of 20µg.kg -1. h -1 . The patient exhibited a bleeding at postoperative day 3,after the modification of NovoSeven ® regimen.At this time,we observed a significant decrease in both ETP and hemoglobin suggesting a correlation between TG capacity and clinical bleeding risk.
Case #2:
In-vitro spiking experiments showed a similar satisfactory efficacy of both NovoSeven® and Feiba ® .The patient's usual home treatment was Feiba ® for which the ex-vivo assessment confirmed haemostastic efficacy.Surgery was performed under Feiba ® 75U.kg -1 given every 8h,with no excessive bleeding.
Case #3:
The patient underwent four orthopedic procedures during the study period.The standardized three-step protocol was performed before each surgery.Results were convergent and they showed a Case #4: The patient was a poor responder to both Feiba ® and NovoSeven ® with unsatisfactory bleeding control with these drugs.In-vitro and ex-vivo TG measurements were performed before the surgery and confirmed the insufficient correction of TG in this particular patient with both Feiba ® or NovoSeven ® .With the knowledge of these results and considering the extremely high risk of the surgery,we designed a strategy that included immunoadsorption in order to eliminate the inhibitor,substitution with FVIII and administration of FEIBA ® when the anamnestic response occurred.The monitoring of this successful strategy using TGT throughout the perioperative period was previously described in a case report (5) . 
